Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF22 antisense RNA 1 (ZNF22-AS1), also known as C10orf25 and FLJ30567, is a long non-coding RNA (lncRNA) located on chromosome 10. It is described as an antisense RNA to the ZNF22 gene, meaning it is transcribed from the DNA strand opposite to the one encoding the ZNF22 gene, but its specific function remains uncharacterized[3]. Antisense RNAs as a class are known to regulate gene expression at various levels, including transcription and RNA processing, typically via cis- or trans-acting mechanisms[2]. However, there is currently no evidence that ZNF22-AS1 functions as a therapeutic target, nor are any drug interactions or roles as a disease biomarker attributed to it. The UniProt entry (Q5T742) lists the protein-coding potential as "uncharacterized," indicating that its protein product, if present, is not functionally defined[3]. Its classification falls under "Other" and "long non-coding RNA," and it is not a receptor, enzyme, transporter, or transcription factor.\n\nSupporting details:\n- ZNF22-AS1 is a long non-coding RNA (lncRNA), part of the antisense RNA category, whose general class is involved in gene expression regulation, but the precise function for this specific molecule is not confirmed[2][3].\n- The protein product, if any, is described as "uncharacterized," and no canonical functional protein isoform is assigned[3].\n- There are no reports of ZNF22-AS1 being pursued as a therapeutic target or having known interacting drugs, mechanism of action, or direct disease affiliation in the literature surveyed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF22 antisense RNA 1 (ZNF22-AS1).